For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Eli Lilly and Company (LLY) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-07): Designation Watch · Gem Score +43 (−100…+100 Quality+Value blend) · Quality 76 · Value 21 · Sentiment 50 (timing only, not weighted) · Composite fair value $1,379.78 vs $1,152.47 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Eli Lilly and Company
LLY NYSEEli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. Headquartered in Indianapolis, Indiana, the company focuses on therapies addressing diabetes, oncology, immunology, neuroscience, and cardiometabolic conditions. Its portfolio includes medicines for chronic metabolic diseases, cancer treatments aimed at specific tumor types, and immunology drugs targeting inflammatory and autoimmune disorders. Eli Lilly and Company serves healthcare systems, hospitals, and pharmacies worldwide, with a strong presence in major markets such as the United States, Europe, China, and Japan. The company operates across the full pharmaceutical value chain, from research and clinical development to large-scale manufacturing and global distribution. Through its focus on innovative, science-driven therapies for complex diseases, Eli Lilly and Company plays a significant role in the healthcare sector, supporting physicians and patients with branded medicines that are integrated into standard treatment protocols across multiple therapeutic areas.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 22.95
Total Equity: N/A
Shares: 899,300,000
Total Debt: $42.50B
Cash: $7.27B
EBITDA: $45.03B
Total Debt: $42.50B
Cash: $7.27B
Revenue: $65.18B
Revenue: $65.18B
Revenue: $65.18B
Total Equity: N/A
Tax Rate: 19.8%
Equity: N/A
Total Debt: $42.50B
Cash: $7.27B
Current Liabilities: $35.23B
Long-Term Debt: $40.87B
Total Debt: $42.50B
Total Equity: N/A
Shares: 899,300,000
Shares: 899,300,000
CapEx: $0.00
Shares: 899,300,000
Stock Price: $1,210
Net Income: $20.64B
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 30, 2026 12:36am (69d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Cost of Revenue | $7.3B | $6.6B | $7.1B | $8.4B | $11.1B |
| Gross Profit | $21.0B | $21.9B | $27.0B | $36.6B | $54.1B |
| Operating Expenses | $13.5B | $13.6B | $7.4B | $8.6B | $11.1B |
| Operating Income | $7.5B | $8.3B | $19.6B | $28.0B | $43.0B |
| Net Income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| EBITDA | $9.1B | $9.8B | $21.2B | $29.8B | $45.0B |
| EPS | $6.15 | $6.93 | $5.82 | $11.76 | $23.00 |
| EPS (Diluted) | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
Balance Sheet (Annual)
Last updated: Jul 30, 2026 12:11am (69d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.8B | $2.1B | $2.8B | $3.3B | $7.3B |
| Total Current Assets | $18.5B | $18.0B | $25.7B | $32.7B | $55.6B |
| Total Assets | $48.8B | $49.5B | $64.0B | $78.7B | $112.5B |
| Current Liabilities | $15.1B | $17.1B | $27.3B | $28.4B | $35.2B |
| Long-Term Debt | $15.3B | $14.7B | $18.3B | $28.5B | $40.9B |
| Total Liabilities | $39.7B | $38.7B | $53.1B | $64.4B | — |
| Total Equity | $9.2B | $10.8B | $10.9B | $14.3B | — |
| Retained Earnings | $9.0B | $10.0B | $10.3B | $13.5B | $24.5B |
Cash Flow (Annual)
Last updated: Jul 30, 2026 12:36am (69d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $7.3B | $7.1B | $4.2B | $8.8B | $16.8B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | -$747.4M | -$327.2M | — | — | — |
| Net Debt Issued / (Repaid) | $501.4M | -$62.0M | $8.6B | $8.9B | $8.1B |
| Dividends Paid | -$3.1B | -$3.5B | -$4.1B | -$4.7B | -$5.4B |
| Stock Buybacks | -$1.3B | -$1.5B | -$750.0M | -$2.5B | -$4.1B |
| Net Change in Cash | $161.4M | -$1.8B | $751.6M | $449.8M | $4.0B |
Growth Trends (YoY %)
Last updated: Jul 30, 2026 12:36am (69d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +0.8% | +19.6% | +32.0% | +44.7% |
| Gross Profit Growth | +4.3% | +23.4% | +35.4% | +47.8% |
| Operating Income Growth | +9.7% | +137.2% | +42.7% | +53.5% |
| Net Income Growth | +11.9% | -16.1% | +102.1% | +94.9% |
| EBITDA Growth | +7.8% | +115.9% | +40.8% | +51.1% |
Dividend History (Last 20)
Last updated: Jul 23, 2026 7:11pm (76d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-15 | $1.73 | — | — | — |
| 2026-02-13 | $1.73 | — | — | — |
| 2025-11-14 | $1.50 | — | — | — |
| 2025-08-15 | $1.50 | — | — | — |
| 2025-05-16 | $1.50 | — | — | — |
| 2025-02-14 | $1.50 | — | — | — |
| 2024-11-15 | $1.30 | — | — | — |
| 2024-08-15 | $1.30 | — | — | — |
| 2024-05-15 | $1.30 | — | — | — |
| 2024-02-14 | $1.30 | — | — | — |
| 2023-11-14 | $1.13 | — | — | — |
| 2023-08-14 | $1.13 | — | — | — |
| 2023-05-12 | $1.13 | — | — | — |
| 2023-02-14 | $1.13 | — | — | — |
| 2022-11-14 | $0.98 | — | — | — |
| 2022-08-12 | $0.98 | — | — | — |
| 2022-05-13 | $0.98 | — | — | — |
| 2022-02-14 | $0.98 | — | — | — |
| 2021-11-12 | $0.85 | — | — | — |
| 2021-08-12 | $0.85 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-06 02:02A +1σ run of quarters pays +35%; a −1σ run costs 21%. Ratio 1.6:1 (μ 43.2%, σ 13.3% , 16 pairs).
| Case | Growth | Margin | Fair value | vs price ($1,152.47) |
|---|---|---|---|---|
| Bull — recovery | +70% | 35.0% | $2,627.60 | +128% |
| Base — stabilizes | +47% | 33.5% | $1,423.85 | +24% |
| Bear — keeps slipping | +23% | 28.5% | $644.19 | -44% |
| Stress — last quarter repeats | +43% | 33.5% | $1,280.11 | +11% |
| Upside — a +1σ run of quarters (v2) | +50% | 33.5% | $1,553.58 | +35% |
| Stress — a −1σ run of quarters (v2) | +30% | 33.5% | $906.25 | -21% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-17 16:25The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Independent read first: LLY's trajectory is genuinely extraordinary but decelerating in the way that matters for a 39x P/E. Quarterly revenue went $11.44B → $15.56B → $17.60B → $19.29B → $19.80B → $22.97B, which is a stunning ramp, but sequential growth compressed from +14.0% (Q4'25) to +2.6% (Q1'26) before re-accelerating to +16.0% in Q2'26 — that's a lumpy pattern consistent with supply-constrained tirzepatide releases, not smooth compounding. Net income margin in the latest quarter dropped to 30.9% from 37.4% and 36.4% a year prior; on a business scaling manufacturing aggressively, some of that is capex flowing through COGS, but at this multiple margin direction matters. TTM revenue is roughly $79.7B and TTM NI ~$26.7B, putting the "real" P/E closer to ~38x on a market cap of $1.01T — expensive but not absurd for a franchise growing revenue ~50% YoY.
Where I part company with the synthesis: the composite fair value of $1,380 (+22.7% upside) leans on a DCF that almost certainly extrapolates the current growth curve too generously. The thesis-evaluation score of -6 (mildly bearish) and the market-narrative "anchored/platform-monopoly" framing are more honest — this stock is priced for a decade of duopoly-like pricing power, and by 2027-2029 you get oral GLP-1s (Lilly's own orforglipron helps, but Novo's competing orals, Amgen's MariTide, Roche/Structure entrants all pressure share), Medicare/CMS pricing exposure, and biosimilar/manufacturing catch-up. The bear weight (78) on competitive collapse of duopoly pricing is directionally correct: gross margin at 83.4% and operating margin at 66% on the annual figures are not sustainable through-cycle for a pharma; consensus long-term pharma op margins are 30-40%. If you haircut steady-state margins to 45% on a $120B revenue base in 2028, you get ~$40B NI — apply 20x and you get ~$800B market cap, i.e., ~20% downside from here before discounting.
The contrarian bull case I'd steelman: obesity TAM is genuinely underestimated — if global penetration reaches even 10% of the ~800M obese adults at durable $500-1000/month net pricing, this is a $40-80B revenue category alone, and Lilly's manufacturing lead (Concord, Kenosha, RTP buildouts) creates a 2-3 year supply moat that captures share before orals commoditize. Pipeline optionality (retatrutide's phase 3 weight loss data, Alzheimer's donanemab ramp, oncology Verzenio still growing) is real free upside not priced by simple DCFs. But note: insider activity shows only sales (6,500 + 2,000 + 5,000 shares in August 2026), zero opportunistic buying. That's not damning at this level, but it's not the pattern of insiders who think the stock is cheap.
Data quality caveats worth flagging: the P/B of 30.5 and D/E of 1.62 reflect a balance sheet where equity has been depleted by buybacks and the $42.5B debt load funds capex — not a red flag but means ROE (102%) is a vanity metric here. FCF of $8.97B against $20.6B net income shows the massive capex drag ($7.84B) — until capex normalizes, "FCF yield" screens will understate cash-generation capability, which cuts in Lilly's favor. The "recent_yoy_span_days: 36500%" is a data artifact — ignore. Macro headwinds flag matters: at a 39x P/E, duration risk is real if 10Y rates stay elevated.
GPT Reading
Lilly’s numbers are extraordinary, but the stock already treats extraordinary as a base case. On a trailing-twelve-month basis through 2026-06-30, revenue is about $79.7B, up roughly 49% from the prior TTM’s roughly $53.3B, while net income has nearly doubled to about $26.7B from roughly $13.8B. That is not “good pharma execution”; that is a step-change in the earnings power of the business. The quarterly cadence shows why investors are willing to suspend normal valuation discipline: sales went from $11.44B in the 2024-09 quarter to $22.97B in the 2026-06 quarter, essentially doubling in seven quarters, and net margin has mostly lived in the low-to-high 30s despite massive growth. Gross margin at 83.4% and TTM net margin at 33.5% say this is not revenue being bought with sloppy commercialization. The business has become a scale monster unusually fast.
What stands out to me, though, is the disconnect between accounting earnings and cash generation in the middle of this hypergrowth phase. 2025 operating cash flow was $16.81B, but free cash flow was only $8.97B because capex hit $7.84B. That is the hidden reality behind the obesity narrative: Lilly is not harvesting a finished franchise, it is still building the physical capacity to supply it. The market cap above $1.0T and enterprise-value-to-revenue around 13.6x imply investors think these investments will convert into years of very high-volume, high-price, high-margin demand with limited competitive erosion. Maybe they will. But at $1,152, investors are paying about 38.7x trailing earnings and roughly 12.96x trailing sales for a large-cap pharma company that still has meaningful execution risk around manufacturing, reimbursement, and category durability. For a software platform, those multiples would be demanding; for a drug company, they require near-flawless continuation.
The annual progression also tells me the stock is valued on a very narrow strategic premise. Revenue moved from $28.3B in 2021 to $65.2B in 2025, and net income from $5.6B to $20.6B, with operating income exploding to $43.0B. That kind of operating leverage is exactly why bulls are emboldened. But because the rerating has already happened, the question is no longer whether Lilly has a great franchise; it is how much of the next five years is prepaid. At over $1T market value against TTM earnings of roughly $26.7B, the company needs to keep compounding at rates that almost no pharma company sustains once supply normalizes and payers push back. I do not need the GLP-1 story to break for the stock to disappoint; I only need growth to slow from spectacular to merely strong. If revenue growth drops from ~50% toward 20%-25% while margins plateau, the current multiple likely compresses even if profits keep rising.
The best argument against my cautious read is that Lilly may simply be earlier in the ramp than skeptics appreciate. The quarterly run-rate is still climbing sharply—$17.60B, then $19.29B, $19.80B, and now $22.97B—and the latest quarter was up nearly 48% from the year-ago June quarter. If supply is still the bottleneck, then current earnings are understating normalized earnings power rather than overstating it. In that scenario, today’s 38.7x trailing P/E could quickly become a much lower forward multiple without any stock decline. The 2025 capex burden can also be read bullishly: Lilly is spending aggressively because demand visibility is unusually high, not because the core business is straining. And unlike many pharma stories, this is not a turnaround hope trade; it is already producing huge profits, with ROA near 22% and a balance sheet that, while levered with $42.5B debt and only $7.27B cash, is supported by a very profitable engine.
What would change my mind is evidence that Lilly can turn this demand spike into sustainably superior cash economics even as the base gets huge. If the next few quarters show revenue holding above $23B and pushing toward $25B+ without net margin slipping below 30%, while operating cash flow annualizes well above $20B and capex begins to normalize, then the case for paying a premium strengthens materially. I would also get more constructive if the company proves that growth can stay above 30% on a TTM basis after supply constraints ease, because that would imply the addressable market and reimbursement runway are broader than I am underwriting. Conversely, if quarterly revenue stalls around the current level, if margins drift back toward the low 20s, or if cash conversion remains weak because manufacturing expansion never catches up cleanly, the stock should not be anywhere near 13x sales. My read is simple: phenomenal company, but the stock is pricing years of dominance with too little room for the normal frictions that always appear in pharma.
Grok Reading
The raw numbers describe a franchise still in vertical ascent, not a mature pharma name that has already plateaued. Trailing-twelve-month revenue through mid-2026 is approximately $79.7B ($22.97 + $19.80 + $19.29 + $17.60), up from the full-year 2025 print of $65.2B and the 2024 base of $45.0B. Sequential quarters have not decelerated: $15.6B → $17.6B → $19.3B → $19.8B → $23.0B. TTM net income of roughly $26.7B implies a trailing net margin near 33.5 percent, consistent with the reported figure, while gross margin sits at 83 percent and operating margin (annual) at 66 percent—elite economics even inside large-cap biopharma. The 2025 free-cash-flow number of $9.0B looks modest against a $1.01 trillion enterprise, but that is almost entirely a function of $7.8B in growth capex; operating cash flow of $16.8B shows the underlying cash engine is already large. At $1,152 the stock trades at 38.7× trailing earnings and 13.0× sales. Those multiples are high in absolute terms, yet they are being applied to a business whose revenue CAGR over the recent window is 43 percent and whose earnings CAGR is 91 percent. The quantitative models that flag “slight upside” to the low-to-mid $1,400s are directionally consistent with the growth still visible in the income statement; the data do not yet show the classic late-cycle fade.
What stands out most is the combination of scale and continued acceleration. A company already printing nearly $23B in a single quarter while still expanding sequential revenue is rare; the manufacturing build-out that is crushing free-cash-flow conversion is the visible cost of protecting that trajectory. Debt of $42.5B against only $7.3B cash is manageable given the cash-flow generation, and ROE above 100 percent (even if partly an artifact of an intangibles-heavy, low-book-value balance sheet) confirms extraordinary capital efficiency on the equity base the market is actually capitalizing. Insider activity is noise—small awards and modest sales—and does not contradict the operating story. The rule-based archetype of high-growth-profitable is correct; the narrative layer that paints LLY as a platform-monopoly GLP-1 compounder is doing real work, but it is work that the last eight quarters of reported results still support rather than merely hype.
The strongest counter-case is valuation durability once the scarcity premium fades. At 39× trailing and roughly 13× sales, the market is embedding multi-year 20-plus percent growth with limited margin compression—an assumption that collides with the thesis-evaluation layer’s top bear points: competitive GLP-1 entrants arriving 2027–2029 and eventual reimbursement ceilings. Free-cash-flow yield under 1 percent leaves almost no cushion if volume growth slows or if pricing power erodes faster than consensus. The composite fair-value exercise itself notes method disagreement and warns that the market already prices more growth than some projections; an 18–23 percent implied upside can evaporate quickly on a single miss or a Novo/Amgen clinical surprise. P/B above 30 and elevated EV/EBITDA simply underline how little tangible-book or steady-state-cash-flow support exists if the obesity narrative loses intensity. I weigh this less heavily than the bulls because the most recent four quarters still show accelerating top-line and stable-to-rising net margins; the competition clock has not yet started ticking in the reported numbers. But the asymmetry is real: disappointment hits a $1 trillion market cap harder than incremental upside surprises.
I would flip to a clear overvalued stance if two consecutive quarters show sequential revenue growth falling below mid-single digits while net margins compress more than 300–400 bps, or if 2027 guidance implicitly prices in a sub-20 percent growth algorithm once new capacity is online. Conversely, sustained quarterly revenue above $25B with FCF conversion rising as capex intensity rolls over would justify pushing the fair-value range toward $1,600-plus and raising conviction.
Qwen Reading local experiment · off-panel
The most glaring contradiction in this dataset is the disconnect between the "high growth" label and the actual quarterly trajectory. While the 43.1% revenue CAGR looks spectacular, the last two quarters tell a different story: revenue grew from $19.80B in Q1 2026 to $22.97B in Q2 2026, a sequential jump of roughly 16%, but the year-over-year growth rate has clearly decelerated from the 93.6% earnings spike seen in the prior year. More concerning is the margin compression: net margin dropped from 37.4% in Q1 2026 to 30.9% in Q2 2026, despite revenue increasing. This suggests that the marginal cost of scaling tirzepatide production is not as low as the "platform monopoly" narrative implies. The market is paying a 38.7x P/E for a company whose operating leverage is currently contracting, not expanding. The $1.01T market cap is not supported by the current cash flow profile; with free cash flow at $8.97B against a market cap of over $1 trillion, the FCF yield is a meager 0.89%. This is a valuation that requires flawless execution for the next five years to justify, yet the data shows the first signs of friction in the supply chain and cost structure.
The balance sheet and insider activity provide further cautionary signals. With total debt of $42.50B against only $7.27B in cash, the net debt position is substantial, and the debt-to-equity ratio of 1.62 is high for a pharma company that is supposed to be a cash cow. The "A-Award" insider transactions are negligible, but the consistent "S-Sale" activity (6,500, 2,000, and 5,000 shares in August 2026) indicates that insiders are taking profits at these levels. While insider selling is common, it is a weak signal when combined with the "Macro Headwinds" and "decelerating" revenue confidence flags. The narrative of a "once-in-a-generation" opportunity is being priced in as if it is a guaranteed outcome, but the data shows a company that is struggling to maintain margin integrity while scaling. The 18.5% discount to DCF cited in the narrative layer is misleading; if the DCF assumes 20%+ growth for a decade, it is ignoring the competitive threat from Novo Nordisk and Amgen, which is not a hypothetical risk but a scheduled event for 2027-2029.
The strongest case against my bearish read is the sheer scale of the addressable market and the current supply constraints. If Eli Lilly can successfully ramp up manufacturing without further margin erosion, the revenue upside is indeed massive. The 83.4% gross margin is still elite, and the 66% operating margin (annual) demonstrates that the core business is highly profitable. The "platform-monopoly" archetype is not without merit; tirzepatide has shown superior efficacy to competitors, which could sustain pricing power even as competition arrives. However, I weigh this differently because the current price of $1,152.46 already reflects a significant portion of this upside. The market is not pricing in a "good" outcome; it is pricing in a "perfect" outcome where LLY maintains its duopoly status and expands the TAM simultaneously. Any stumble in manufacturing or a pricing concession to insurers would trigger a violent re-rating, as there is no cushion in the multiple.
What would change my mind is a clear demonstration of margin expansion in the next two quarters. If net margin recovers to above 35% while revenue continues to grow at 20%+ year-over-year, it would prove that the cost curve is bending in LLY's favor and that the scale is working. Additionally, a significant reduction in net debt or a buyback announcement would signal management confidence in the cash flow sustainability. Conversely, if we see a further drop in net margin below 30% or a guidance cut on 2027 revenue, the valuation becomes indefensible. The current setup is a high-risk, high-reward bet on execution, but the data suggests the risk is currently outweighing the reward.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has more than doubled from 29.1B in 2022 to 79.7B in the TTM through mid-2026, with gross margin expanding from 76.0% to 83.4% and net income rising from 5.7B to 26.7B. Free cash flow has scaled from 6.1B to 28.1B, and OCF/NI of 0.93x with accruals at 0.7% of assets, Beneish M of -2.01, and Altman Z of 6.63 indicate that this growth is being converted to real cash with no mechanical earnings-quality flags. Diluted share count has actually shrunk slightly (-0.3% CAGR) with SBC only 0.8% of revenue and buybacks running at ~485% of SBC, so per-share value is being protected, not diluted, even during a massive capacity build.
Verify before trusting this (6)
- Debt maturity ladder and covenants against the 46B net debt position
- Capex trajectory and how much of current FCF conversion is capex-suppressed
- Incretin franchise revenue concentration (Mounjaro/Zepbound as % of total)
- Pipeline depth beyond tirzepatide (orforglipron, retatrutide progress)
- Pricing/rebate pressure and Medicare negotiation exposure
- R&D spend trend as % of revenue amid the top-line surge
The e2e composite fair value sits at $1,379.78 with a signal-adjusted $1,414.27, implying roughly 20-23% upside from the $1,152.47 price. The anchored-PE method drives that, which is defensible here because earnings quality is clean (score 1, no haircut warranted) and the Fortress quality grade justifies a premium multiple. This is not a runaway DCF miles above spot; the FV is within a sane band for a franchise growing revenue nearly 3x in four years with expanding gross margins and shrinking share count. So the deserved value math holds up to sanity checks. What is priced in at $1,152: continued GLP-1 dominance, successful capacity scale-up, and durable pricing into the late 2020s. What is NOT fully priced: the option value of pipeline extensions (orforglipron oral, retatrutide) and Zepbound share gains as supply catches demand. The gap is real but not extreme - roughly 20% margin of safety on a mega-cap that the market understands well. That is the textbook 'modestly cheap' zone, not deep value. A 20% cushion on a Fortress business is worth owning; it is not worth backing up the truck. Bear risks (Novo competition, pricing pressure, any efficacy or safety headline) could compress the multiple fast given how much growth is embedded.
Verify before trusting this (5)
- Zepbound/Mounjaro quarterly script trends and any pricing/rebate commentary
- Orforglipron and retatrutide phase 3 readouts and timing
- Capacity ramp progress and any supply constraint updates
- Guidance on operating margin trajectory as manufacturing scales
- Any commentary on CMS/Part D negotiation exposure
The dominant force on LLY is narrative, not macro. The market tells a strong platform-monopoly story around Mounjaro/Zepbound with moderate durability and a medium cult following, and the recent news flow reinforces it: Berenberg upgrade to Buy with a $1,400 target (roughly 20% upside), Foundayo UK approval expanding the GLP-1 franchise into pills, a 48% Q2 revenue print, and multiple AI drug-discovery tie-ups (TuneLab with Twist and Ginkgo) that layer a secondary AI-in-pharma halo on top. Momentum is strong-positive (49.6% recent vs 43.1% long-term), and big-move history shows the tape rewards LLY-specific catalysts quickly. The risk-off market regime (VIX 17.7, S&P off highs) is a real crosswind but LLY's 0.5 beta and defensive pharma classification mute it substantially - we even saw explicit rotation OUT of expensive tech INTO LLY on Aug 18. Offsets are genuine but secondary: a -7% month, price-cut concerns (US price -9% y/y), and a running debate that the stock prices in perfection with Novo/Amgen competition looming. Analyst tone is tilting up, the narrative is intact and being fed, and the macro drag lands lightly on a low-beta defensive - net pressure leans tailwind.
Verify before trusting this (4)
- Whether the Berenberg upgrade triggers follow-on target raises from bigger sell-side names
- Any Q3 read-through on US net pricing - a second consecutive decline would validate the bear pricing-pressure frame
- Amgen/Novo GLP-1 trial readouts that could dent the monopoly narrative
- Whether the risk-off regime deepens beyond VIX 20 and drags even defensives lower
The world's demand shift is toward chronic metabolic treatment as a primary-care staple rather than a specialty intervention, and LLY sits at the supply chokepoint of that shift. Macro headwinds (10y near 5%, mild curve) matter little to a franchise whose constraint is fill-finish capacity, not consumer credit — though they raise the cost of the capex build and compress payer budgets at the margin. The live structural question is not demand but who captures the value: as governments and PBMs move from rationing access to negotiating price, the category's dollars grow while price per unit falls. That trade favors LLY's volume-led model for the next several years and turns against it as oral competitors qualify supply late this decade.
When we made this prediction on Sep 18, 2026, LLY was $1,144.31. We expect it to be $1,060.00 by Mar 2027, and we consider it great value under $1,050.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Sep 18, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
trailing_eps
flips down 25%
adjusted_pe
flips down 25%